Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 6.04B |
| Revenue (ttm) | 92.29M |
| Net Income (ttm) | -59.29M |
| Shares Out | 199.01M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $30.35 |
| Previous Close | $31.35 |
| Change ($) | -1.00 |
| Change (%) | -3.19% |
| Day's Open | 31.41 |
| Day's Range | 29.83 - 31.41 |
| Day's Volume | 1,582,624 |
| 52-Week Range | 3.57 - 53.69 |
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Pacific Biosciences of California Inc (NASDAQ: PACB) has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform. Under the terms of the agreement, PacBio will ...
Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc.
MENLO PARK, Calif. and SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-r...
MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results ...
You can get a lot of bang for the buck with these picks.
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing HiFi Sequen...
MENLO PARK, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platf...
Industry Veteran Will Lead PacBio's Commercial Footprint Across the Region Industry Veteran Will Lead PacBio's Commercial Footprint Across the Region
Twenty years after the human genome was sequenced, a new wave of discovery has begun.
A new breed of disruptors is delivering breakthroughs in genomics.
Incredible scientific advances could reward investors -- if they have the patience.
Falling costs are ushering in a new era of screening for a dreaded disease.
MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
The company released its first-quarter earnings report, but that doesn't tell the whole story.
Shares of Pacific Biosciences (NASDAQ:PACB) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 4600.00% over the past year to ($0.45), which we...
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.
MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr...
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results ...
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
These two disruptive companies have long growth runways ahead of them.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4% over the...
Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.
Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing and a miss ...
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...
The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, which beat...
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Re...
Pacific Biosciences is getting an investment from a holding company.
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today an...
SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% ...
Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.
On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...
A new leadership team is betting that it can make long-read genome sequencing more competitive.
MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonuclease... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 27, 2010 |
| Stock Exchange NASDAQ | Ticker Symbol PACB |
Analyst Forecasts
According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 47.25, which is an increase of 55.68% from the latest price.